Sun, Dec 28, 2014, 12:06 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • swhitemd50 swhitemd50 Nov 3, 2011 2:34 PM Flag

    From VRUS's conference call

    Listening to the VRUS conference Q&A, it is apparent what their game plan is regarding the treatment of genotype 1 HCV. My guess is that their all-oral PSI-7977/ribavirin cure rate will be very inferior to Incivek/peg-interferon/ribavirin but they will say that it is a superior regimen because most patients cannot/will not tolerate interferon.

    From the conference Q&A:

    "...88% of veterans who have HCV infection have not been treated. And again, a majority of those are because they are ineligible for interferon therapy." -- M. Michelle Berrey

    "With respect to the competitiveness clearly an interferon free regimen, any SVR is actually a significant improvement." -- PATRICK T. HIGGINS

    This is the first time I have heard that most patients are "ineligible" for interferon therapy. I think it's B.S., especially with Incivek's shortened treatment durations for many patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Listening to the VRUS conference Q&A, it is apparent what their game plan is regarding the treatment of genotype 1 HCV. My guess is that their all-oral PSI-7977/ribavirin cure rate will be very inferior to Incivek/peg-interferon/ribavirin but they will say that it is a superior regimen because most patients cannot/will not tolerate interferon.

      From the conference Q&A:

      "...88% of veterans who have HCV infection have not been treated. And again, a majority of those are because they are ineligible for interferon therapy." -- M. Michelle Berrey

      "With respect to the competitiveness clearly an interferon free regimen, any SVR is actually a significant improvement." -- PATRICK T. HIGGINS

      This is the first time I have heard that most patients are "ineligible" for interferon therapy. I think it's B.S., especially with Incivek's shortened treatment durations for many patients."
      -----------------------------
      Swhitemd,

      Outright inaccurate and false statement like the above indicates the mindset of management at VRUS.

      It reminds me of SGP's hyping of Boceprevir (vitrelis) way back. They were massaging the data with all sort of tricks to make their data look better than Incivek. In fact there was an internet site citing and making fun of their shenanigans.

      Of course such deception on SGP management's part worked well for their sharholders because they coned MRK to pay a hefty price to buy the company only to find that their prize drug, Victrelis, was not such a prize after all

    • I'm not going to defend Michelle's statement but she did refer to a study if I recall. There are a high percentage of patients that are interferon-intolerant and/or contraindicated. The awful side effects of interferon IMO is reason enough to wait a year and a half for oral treatment or enroll in the ongoing oral studies.

      • 1 Reply to vnfin
      • Michelle's statement was that there was a study that showed 88% of veterans with HCV had not been treated. But it is unclear if her next statement (about ineligibility for interferon therapy being the reason they were not treated) was supported by this study. I am inclined to believe it had more to do with patients/docs not wanting 48 weeks of interferon with only a 40% cure rate. With Incivek's 79% cure rate and, in many cases, shortened interferon treatment duration, I think most patients will now be eligible for Incivek/interferon/ribavirin.

 
VRTX
118.41+3.26(+2.83%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.